Menu
Montecito
American Riviera
Loading...
You are here:  Home  >  Biotech
Latest

New CEO, new board chair, new funding for ImmPact Bio

By   /  Thursday, January 20th, 2022  /  Biotech, Central Coast Health Watch, East Ventura County, Latest news, Startups, Technology, Top Stories, Tri-County Economy  /  Comments Off on New CEO, new board chair, new funding for ImmPact Bio

Camarillo-based ImmPact Bio made multiple headlines with one announcement on Jan. 20: the a new CEO, a new board chair, and the closing of a $111 million Series B funding round. ImmPact, a biotechnology company developing cancer treatments based on chimeric antigen receptor (CAR) T-cell therapies, named Sumant Ramachandra as its new president and CEO. Read More →

Read More →
Latest

Amgen inks drug development deal worth up to $1.9B

By   /  Friday, January 7th, 2022  /  Banking & Finance, Biotech, Central Coast Health Watch, East Ventura County, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen inks drug development deal worth up to $1.9B

Thousand Oaks-based Amgen has reached an agreement with Generate Biomedicines, a Massachusetts-based therapeutics company, to research, discover and create protein therapeutics, the company announced Jan. 6. According to the agreement, Amgen, one of the largest biotech companies in the world, will pay $50 million up front to fund the initial five programs, with a potential Read More →

Read More →
Latest

Capsida’s new CEO hopes success is in the genes

By   /  Friday, January 7th, 2022  /  Biotech, East Ventura County, Latest news, Subscriber content, Technology, Top Stories, Top Story, Tri-County Economy  /  Comments Off on Capsida’s new CEO hopes success is in the genes

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

2021: The Year In Review

By   /  Friday, December 31st, 2021  /  Banking & Finance, Biotech, Central Coast, Central Coast Health Watch, Latest news, Technology, Top Stories, Tri-County Economy  /  No Comments

The Dec. 31 print edition of the Pacific Coast Business Times marks our annual Year In Review, featuring the biggest and best stories we published in 2021. Here is a look through our archives at the past year, a year marked by big deals, economic recovery and public health victories, but also by recurring waves Read More →

Read More →
Latest

Amgen’s new asthma treatment gets FDA approval

By   /  Wednesday, December 22nd, 2021  /  Banking & Finance, Biotech, Central Coast Health Watch, East Ventura County, Latest news, Subscriber content, Technology, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen’s new asthma treatment gets FDA approval

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Capsida names new CEO

By   /  Tuesday, December 7th, 2021  /  Biotech, Central Coast Health Watch, East Ventura County, Latest news, Technology, Top Stories, Tri-County Economy  /  Comments Off on Capsida names new CEO

Capsida Biotherapeutics, a venture-backed Thousand Oaks company developing gene therapy treatments, announced the hiring of a new CEO on Dec. 7. In April, Capsida emerged from “stealth mode” and closed a $140 million series A funding round, one of the largest venture capital raises of the year in the region’s life sciences sector. Capsida is Read More →

Read More →
Latest

MannKind reports higher revenue, lower losses in Q3

By   /  Wednesday, November 10th, 2021  /  Banking & Finance, Biotech, Earnings, East Ventura County, Latest news, right, Technology, Top Stories, Tri-County Economy, Tri-County Public Companies  /  Comments Off on MannKind reports higher revenue, lower losses in Q3

MannKind Corp. reported a substantial rise in revenue and a shrinking net loss in the third quarter of 2021 on Nov. 9, despite news since the quarter ended that the U.S. Food and Drug Administration will not yet approve a hypertension treatment the company is developing with United Therapeutics. MannKind, a Westlake Village-based biotechnology company Read More →

Read More →